Editor´s Pick

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

PARIS--(BUSINESS WIRE)--SpikImm, a Paris-Based biotechnology company and Institut Pasteur reports that SPKM001, their high affinity human monoclonal antibody, potently neutralizes the original SARS-CoV-2 strain...

Admin - September 8, 2021

Editor´s Pick

Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase...

Admin - September 2, 2021

Editor´s Pick

FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy,...

Admin - August 31, 2021

Editor´s Pick

Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has completed the rolling submission...

Admin - August 25, 2021

Editor´s Pick

Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application...

Admin - August 25, 2021

Editor´s Pick

PharmaJet Partner Zydus Cadila Announces Emergency Use Authorization Approval for World’s First Plasmid DNA COVID-19 Vaccine

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization (EUA)...

Admin - August 23, 2021

12 3...58 Page 1 of 58

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

Regulatory Affairs September 17, 2021